# Wall Street's Wildest Showdowns: Bulls vs. Bears! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-10-01T02:35:01.905Z Source: https://newsyai.com/edition/309d22d1-6f7b-4956-b0ab-78d36f524382 Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- **Wall Street's Most Polarizing Shitshows: 3 Stocks Where Bulls and Bears Are Still Throwing Hands (and Maybe Some Feces) — Fresh Edition, October 1, 2026** Futures mixed—Dow flat, Nasdaq mainlining the AI hype like it's the fountain of youth, crude oil bouncing like a caffeinated squirrel on a trampoline. Last round's server hardware, telehealth subscriptions, and fintech banking plays? Yesterday's news. These three tickers have the Street more divided than a crypto bro at a family reunion. Elevated short interest across the board (flirting with 30-80%+ of float in recent screens, with days-to-cover that screams volatility potential), fresh short data, filings, and chatter only—no reruns. Bulls see structural tailwinds and squeeze fuel; bears see execution flops, dilution landmines, competition overhangs, and fading relevance. Then the first-principles hammer drops.[[1]](https://www.tipranks.com/screener/most-shorted-stocks)[[2]](https://www.thetrading.tools/short-interest) ### 1. VG (Venture Global) – LNG Export Beast or Debt-Laden Delay Disaster? VG carries sky-high short interest (~80% of float in recent readings), as the LNG exporter navigates global energy demand, project ramps, and balance-sheet scrutiny.[[3]](https://www.benzinga.com/short-interest/most-shorted) **Bull Case (The "Europe and Asia Can't Get Enough Gas, Contracts Are Locked, and 'This Time Production Hits on Schedule' Crew)** Bulls highlight surging LNG demand from energy-hungry regions, any progress on facility startups or offtake deals, long-term tailwinds from the global shift away from dirtier fuels, and potential for massive rebounds if macro energy prices or geopolitics accelerate. Some see it as a high-conviction infrastructure bet with short interest as squeeze ammo on positive operational updates or earnings beats. **Bear Case (The "Delays Pile Up Like Unpaid Bills, Debt Crushes Margins, Competition from Bigger Players Looms, and 'Will It Ever Be Truly Cash-Flow Positive?' Crew)** Bears hammer ongoing leverage in a capex-heavy industry, risks around construction hiccups, regulatory or supply-chain snarls, pricing pressure, and doubts that the setup justifies exposure amid macro energy scrutiny and competitive realities. Short buildup reflects skepticism that hype justifies the risk amid financial and execution headwinds. **My First-Principles Take**: Energy infrastructure value accrues to operators with reliable project execution, locked-in offtake, efficient capital allocation, clear paths to positive free cash flow or stable margins, and defensible scale advantages—economics reward operational discipline and market adaptation over pure volume bets in a cyclical, regulation-, and capex-sensitive field. VG has genuine tailwinds from LNG demand growth, but durable shareholder value only comes if ramps convert without endless resets, differentiation holds vs. incumbents, and operations turn sales into profits without perpetual volatility. The export bet is directionally exposed to energy transition and security needs, yet it's an execution-, leverage-, and sentiment-sensitive play prone to binary swings. At these short levels, volatility grenade—positive catalysts roast shorts; stumbles feed the fire. High-risk, high-reward for the bold. ### 2. CLSK (CleanSpark) – Bitcoin Mining Pivot King or Crypto Volatility Cash Furnace? CLSK sports elevated short interest (~40%+ in targeted screens), as the Bitcoin miner navigates crypto cycles, energy costs, and any AI/data-center diversification.[[4]](https://www.benzinga.com/trading-ideas/movers/26/09/62004722/squeeze-watch-10-stocks-with-over-33-short-interest) **Bull Case (The "Bitcoin Adoption Roars, Hashrate Grows, Energy Assets Shine, and 'This Time AI Compute Actually Adds' Crew)** Bulls point to ongoing crypto demand and mining economics, any progress on fleet expansion, efficiency gains, or new revenue streams versus traditional miners, long-term tailwinds from digital assets and power infrastructure, and potential for massive rebounds if macro risk appetite or Bitcoin prices accelerate. Some see it as a high-conviction recovery/growth play with short interest as squeeze ammo on positive operational milestones or earnings beats. **Bear Case (The "Halving Bites Hard, Energy Prices Eat Margins, Competition Eats Share, and 'Will It Ever Be Truly Profitable Through Cycles?' Crew)** Bears hammer ongoing growth investments and leverage, risks around crypto volatility, pricing pressure, and capacity issues, history of execution hiccups in a crowded mining space, and doubts that the setup justifies exposure amid macro rate and competitive scrutiny. Short buildup reflects skepticism that hype justifies the risk amid operational and market realities. **My First-Principles Take**: Digital asset infrastructure value accrues to operators with scalable, low-cost energy access, efficient capital use, clear paths to positive free cash flow or stable revenue streams, and defensible operational edges—economics reward operational discipline and market adaptation over pure expansion bets in a cyclical, volatility-, and competition-sensitive field. CLSK has genuine tailwinds from Bitcoin network growth and potential power plays, but durable shareholder value only comes if expansions convert without endless resets, differentiation holds vs. bigger players, and operations turn activity into profits without perpetual cycles. The mining bet is directionally exposed to crypto and compute shifts, yet it's an execution-, leverage-, and sentiment-sensitive play prone to swings. At these short levels, volatility grenade—positive catalysts roast shorts; stumbles feed the fire. High-risk, high-reward for the bold. ### 3. BEAM (Beam Therapeutics) – Precision Gene Editing Pioneer or Clinical Cash Burn Machine? BEAM features notable short interest (~35-40% range in recent biotech screens), as the base-editing biotech navigates clinical pipelines, regulatory paths, and funding needs.[[4]](https://www.benzinga.com/trading-ideas/movers/26/09/62004722/squeeze-watch-10-stocks-with-over-33-short-interest) **Bull Case (The "Genetic Medicine Boom Never Dies, Pipeline Hits Catalysts, and 'This Time Safety and Efficacy Actually Scale' Crew)** Bulls highlight ongoing demand for precision therapies, any progress on clinical data, partnerships, or platform validation versus traditional approaches, long-term tailwinds from unmet disease needs, and potential for massive rebounds if macro biotech spending or approval momentum accelerates. Some see it as a high-conviction recovery/growth play with short interest as squeeze ammo on positive operational updates or trial beats. **Bear Case (The "Regulatory and Clinical Risks Bite Hard, Competition from CRISPR Eats Share, Cash Burn Stays High, and 'Will It Ever Be Truly Profitable?' Crew)** Bears hammer ongoing R&D investments, risks around trial failures, pricing pressure, and regulatory scrutiny in biotech, history of execution hiccups in a crowded gene-editing market, and doubts that the setup justifies exposure amid macro funding and policy scrutiny. Short buildup reflects skepticism that hype justifies the risk amid operational and competitive realities. **My First-Principles Take**: Biotech platform value accrues to operators with scalable manufacturing or delivery, efficient capital use, clear paths to positive free cash flow or approved products with pricing power, and defensible IP/moat edges—economics reward operational discipline and market adaptation over pure R&D bets in a cyclical, regulation-, and competition-sensitive field. BEAM has genuine tailwinds from precision editing promise and disease targets, but durable shareholder value only comes if candidates advance without endless resets, differentiation holds vs. bigger players, and operations turn science into profits without perpetual dilution. The editing bet is directionally exposed to therapeutic innovation, yet it's an execution-, funding-, and sentiment-sensitive play prone to swings. At these short levels, volatility grenade—positive catalysts roast shorts; stumbles feed the fire. High-risk, high-reward for the bold. There you have it—three fresh brawls proving disagreement is the market's favorite drug. Do your own damn homework, size like an adult, and remember: the tape stays irrational longer than your margin account can breathe. Sources pulled from latest short interest data (e.g., via TipRanks, Benzinga, Find My Moat, and related screens), company filings/press releases, analyst notes, and options flow as of late September/early October 2026. Trade responsibly, you magnificent animals.